Sickle Cell Disease Treatment Market on the Rise Projected to Hit USD 6.94 Billion by 2030, Driven by a Strong 18.8% CAGR from 2030 | Key Players- Alnylam Pharmaceuticals Inc, Baxter International Inc, Bristol-Myers Squibb Company

𝐀𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐚𝐧 𝐞𝐱𝐡𝐚𝐮𝐬𝐭𝐢𝐯𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐬𝐢𝐜𝐤𝐥𝐞 𝐜𝐞𝐥𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐟𝐨𝐫 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐝𝐞𝐜𝐚𝐝𝐞. 𝐈𝐧 𝟐𝟎𝟐𝟏, 𝐠𝐥𝐨𝐛𝐚𝐥 𝐬𝐚𝐥𝐞𝐬 𝐢𝐧𝐜𝐨𝐦𝐞 𝐫𝐞𝐚𝐜𝐡𝐞𝐝 𝐔𝐒𝐃 𝟏.𝟓𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐚𝐭 𝐚 𝐫𝐨𝐛𝐮𝐬𝐭 𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐀𝐧𝐧𝐮𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟏𝟖.𝟖%, 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟔.𝟗𝟒 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎.

Handling of sickle cell anemia is normally targeted at circumventing pain incidents, mitigating indications, and prohibiting obstacles. Treatments may involve medication and blood transfusion. For some children and teenagers, a stem cell transplant might heal the disease. Gene therapies are also being advanced that might provide restoration for people with sickle cell disease. One of the medications taken is hydroxyurea, which decreases the affliction crises and might decrease the requirement for blood transfusions and hospital stopovers. But it can escalate the probability of infections.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐀 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐨 𝐆𝐚𝐢𝐧 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/sickle-cell-disease-treatment-market/request-for-sample

𝐆𝐫𝐨𝐰𝐭𝐡 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

• The market for sickle cell disease treatment is expanding due to the massive growth in the aggregate of people developing SCD is one of the prominent reasons influencing the market demand for new drugs that can productively convey disease treatment.
• Haemoglobin issues are inherent blood diseases engendered by the transference of flawed hemoglobin genes from both parents who are usually fit. Each year, approximately 300,000 new born with grave haemoglobin deformities. Therefore, several nation's health government controllers are concentrating on accelerating the permission of inventive therapeutic processes supporting the sickle cell disease treatment market.
• The escalated existence of sickle cell disease in both advanced and advancing nations is the main propeller of the market in both regions. The government and alternate regulatory bodies are pushing their capital disbursing help for additional advancement and research.

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐏𝐫𝐨𝐟𝐢𝐥𝐞

Critical players are acquiring policies such as commodity advancement, compliance, partnerships, and acquisitions to brace their market positions.

Major companies in the sickle cell disease treatment market are noted below:
• AstraZeneca Plc.
• Acceleron Pharma
• Inc.
• Arena Pharmaceuticals
• Inc.
• Alnylam Pharmaceuticals Inc.
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Bluebird bio Inc.
• Emmaus Life Sciences Inc.
• Eli Lilly and Company
• Global Blood Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• Sangamo Therapeutics

𝐂𝐥𝐢𝐜𝐤 𝐨𝐧 𝐭𝐡𝐞 𝐁𝐞𝐥𝐨𝐰 𝐋𝐢𝐧𝐤 𝐭𝐨 𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/buy/1558/2

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐒𝐜𝐨𝐩𝐞

The regions covered in the report are Europe, North America, Latin America, Asia Pacific, Middle East & Africa.

𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐢𝐜𝐤𝐥𝐞 𝐂𝐞𝐥𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

• Emergence of Gene Therapy:
CRISPR-Cas9 and Gene Editing: Technologies like CRISPR-Cas9 are being explored to correct the genetic defect that causes SCD, offering potential curative therapies. Clinical trials and research into gene-editing solutions are increasing.
• Development of Novel Pharmaceuticals:
New Drug Approvals: Recent FDA approvals of drugs like voxelotor and crizanlizumab represent significant advancements in SCD treatment. These drugs focus on reducing hemolysis and vaso-occlusive crises, respectively.
• Focus on Pain Management:
Chronic Pain Solutions: As pain is a major symptom of SCD, there is increasing research and development in both pharmacological and non-pharmacological pain management strategies.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤

By Treatment
• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

By End-Use
• Hospitals
• Specialty Clinics
• Others

𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/sickle-cell-disease-treatment-market

𝐒𝐢𝐜𝐤𝐥𝐞 𝐂𝐞𝐥𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• Bone Marrow Transplant (BMT) segment is anticipated to grow at a significant CAGR over the forecast period. Only bone marrow transplantation (BMT) can cure SCD. As a result, the preference for BMT is growing throughout North America and Europe. However, the procedure's high cost and difficulties in locating a matched donor restrict the segment's growth.

• Pharmacotherapy segment accounted for a significant revenue share. The government's significant support for pharmaceutical businesses can be ascribed to the segment's rapid expansion. Because there are currently few therapy choices on the market, the government encourages research through financing and classifications like orphan pharmaceuticals, fast track, issues that will affect, and others.

• Asia Pacific is expected to grow at a lucrative CAGR over the projected period. Because of a rising patient population and increasing disposable income levels in this region. Furthermore, the expansion of the healthcare system and increasing government efforts would accelerate the market's growth in this region.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐖𝐢𝐝𝐞-𝐫𝐚𝐧𝐠𝐢𝐧𝐠 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐨𝐟 𝐏𝐌𝐑'𝐬 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Telehealth Market: https://www.polarismarketresearch.com/industry-analysis/telehealth-market

Hearing Aids Market: https://www.polarismarketresearch.com/industry-analysis/global-hearing-aids-market

Anti-Snoring Devices And Snoring Surgery Market: https://www.polarismarketresearch.com/industry-analysis/global-anti-snoring-devices-and-snoring-surgery-market

Psoriasis Drug Market: https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market

Anti-Aging Market: https://www.polarismarketresearch.com/industry-analysis/anti-aging-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.